Publication Venue For

  • A chimeric Sindbis-based vaccine protects cynomolgus macaques against a lethal aerosol challenge of eastern equine encephalitis virus.  31:1464-1470.
  • A dilemma for mucosal vaccination: Efficacy versus toxicity using enterotoxin-based adjuvants.  20:2431-2438.
  • A randomized phase II trial to compare safety and immunogenicity of the MVA-BN smallpox vaccine at various doses in adults with a history of AIDS.  38:2600-2607.
  • Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential.  24:6859-6866.
  • Co-administration of cholera toxin and apple polyphenol extract as a novel and safe mucosal adjuvant strategy.  27:4808-4817.
  • Effectiveness of the B subunit of cholera toxin in potentiating immune responses to the recombinant hemagglutinin/adhesin domain of the gingipain Kgp from Porphyromonas gingivalis.  23:4734-4744.
  • Gonococcal vaccines: Public health value and preferred product characteristics; report of a WHO global stakeholder consultation, January 2019.  38:4362-4373.
  • HPV vaccine uptake among daughters of Latinx immigrant mothers: Findings from a cluster randomized controlled trial of a community-based, culturally relevant intervention.  38:4125-4134.
  • Helper Th1 and Th2 cell responses following mucosal or systemic immunization with cholera toxin.  12:903-911.
  • Immune intervention strategies for HIV-1 infection of humans in the SIV macaque model.  20.
  • Immunization of mice with poliovirus replicons expressing the C-fragment of tetanus toxin protects against lethal challenge with tetanus toxin.  15:257-264.
  • Lipopolysaccharide-specific memory B cell responses to an attenuated live cholera vaccine are associated with protection against Vibrio cholerae infection.  36:2768-2773.
  • Peak frequencies of circulating human influenza-specific antibody secreting cells correlate with serum antibody response after immunization.  28:3582-3587.
  • Pneumococcal vaccination in older adults induces antibodies with low opsonic capacity and reduced antibody potency.  26:5521-5526.
  • PspA, a protection-eliciting pneumococcal protein: Immunogenicity of isolated native PspA in mice.  14:858-867.
  • Role of CD80 and CD86 in host immune responses to the recombinant hemagglutinin domain of Porphyromonas gingivalis gingipain and in the adjuvanticity of cholera toxin B and monophosphoryl lipid A.  25:6201-6210.
  • Systemic Lupus Erythematosus: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data.  34:6572-6581.
  • The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae.  19.
  • International Standard Serial Number (issn)

  • 0264-410X